Mizuho raises Sage Therapeutics target to $9 on Biogen bid
Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...
Biogen's SWOT analysis: neurology giant faces pipeline hurdles, stock outlook mixed
Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...
pharmaphorum22h
Biogen offers to buy out wilting Sage for $442 million
Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...
pharmaphorum22h
Sage takes another hit as Alzheimer's drug is canned
Last month, Sage reported that Biogen had ducked out of a collaboration on a drug codenamed SAGE-324 for essential tremor, a debilitating neurological disorder that causes involuntary and rhythmic ...
Biogen (BIIB) Gets a Hold from Piper Sandler
In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...
eLife22h
Phosphoglycerate mutase regulates Treg differentiation through control of serine synthesis and one-carbon metabolism
The results highlight an important physiological function of PGAM in the differentiation and suppressive activity of Treg cells by regulating serine synthesis. This role is proposed to intersect with ...